2006, Number 2
PDF size: 200.13 Kb.
ABSTRACTIntroduction: Sialorrhoea is a disabling problem in many patients affected by neurological disorders. Anticholinergic drugs often produce side effects in these patients. Botulinum toxin A (TBA) blocks liberation of acetylcholine in motor and autonomic nerve terminals. Materials and methods: We report preliminary data about 8 patients with Parkinson’s disease (PD), and 4 patients with sclerosis lateral amyotrophic (ELA). All of them underwent treatment with TBA in both parotid glands to treat sialorrhoea, and were prospectively evaluated. Severity and Frequency Sialorrhoea Scale was used pre-treatment and at 4 weeks (1 month), 12 weeks (3 Months). TBA was administered in two points in each parotid gland, and one point in submaxillary gland; only in 2 patients of PD and 1 of ELA required new injection at 2 weeks only in parotid gland, with a dose ranging between 75 Us and 100 units in each point (1.5 Us by kg). Results: Three females and five males, with a men age of 63.6 ± 7 years are reported. Four patients with PD (4 males), and 4 patients (2 males and 2 females) to ELA. Sialorrhoea pre-treatment severity score was 5 in 5 patients; while pre-treatment frequency score was 4 (continuous sialorrhoea all the days) in 3 patients. Four weeks after TBA injection, six patients scored lowered 2 in severity and 2 only 1. Three patient with ELA with mild sialorrhoea (score 3) pre-treatment, after 4 weeks of treatment dismissed to score 2 in one patients sialorrhoea disappear. No side effects were observed after TBA injections at 4-12 weeks follow-up. Conclusions: Trans-dermic injection of TBA is safe and effective technique to treat sialorrhoea in neurological diseases when used by neurologists with experience, without side effects.
Pal PK, Calne DB, Calne S, Tsui JKC. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000; 54: 244-7.
Rose FC. The management of motor neuron disease. Adv Exp Med Biol 1987; 209: 167-74.
Crysdale WS, White A. Submandibular duct relocation for drooling: a 10-year experience with 194 patients. Otolaryngol Head Neck Surg 1989; 101: 87-92.
Aguilar RF. Nuevas indicaciones de la toxina botulínica tipo A. Plast & Rest Neurol 2005; 4: 25-30.
Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment for cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633-9.
Aguilar-Rebolledo F. Espasticidad y Toxina Botulínica. Cap. 27, Ed. DEMSA México 2008: 361-363.
Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis. Randomized, single- blind, two-dose study. Neurology 2001; 57: 2095-9.
Karamfilov T, Konrad H, Karte K, Wollina U. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. Arch Dermatol 2000; 136: 487-90.
Naumann M, Jost WH, Toyka KV. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 1999; 56: 914-6.
Jongerius PH, Rotteveel JJ, van den Hoogen E, Joosten F, van Hulst K, Gabreels FJ. Botulinum toxin A: A new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 2001; 160: 509-12.
Shaari CM, Wu B, Biller HF, Chuang S, Sanders I. Botulinum toxin decreases salivation from canine submandibular glands. Otoryngol Head Neck Surg 1998; 118: 452-7.
Ellies M, Laskawi R, Götz W, Arglebe C, Tormahler G. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 1999; 256: 148-52.
Bushara OK. Sialorrhoea in amyotrophic lateral sclerosis: a hypothesis of a new treatment- botulinum toxin A injections of the parotid glands. Med Hypotheses 1997; 48: 337-9.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
Fahn S, Elton RL, and Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CDE, Calne D et al. Recent developments in Parkinson’s disease, 2. Florham Park: MacMillian Healthcare Information, 1987: 153-63.
O’Sullivan JD, Bhatia KP, Lees AJ. Botulinum toxin as a treatment for drooling saliva in PD. Neurology 2000; 55: 606-7.
Jost WH. Treatment of drooling in Parkinson´s disease with botulinum toxin. Mov Disord 1999; 14: 1057.
Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121-3.
Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001; 70: 538-40.
Winterholler MGM, Erbguth FJ. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effect of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70: 417-8.
Mezaki T, Kaji R, Kohara N, Kimura J. Development of general weakness in a patient with amyotrophic lateral sclerosis alter focal botulinum toxin injection. Neurology 1996; 46: 845-6.
Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation alter botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001; 150: 95-7.
Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W. Botulinum toxin to reduce saliva flow: selected indication for ultrasound-guided toxin application into salivary glands. Laryngoscope 2002; 112: 82-6.
Glickman S, Deaney CN. Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 2001; 8: 567-71.